JP2024534901A - シヌクレイノパチーの予防及び治療のための方法 - Google Patents

シヌクレイノパチーの予防及び治療のための方法 Download PDF

Info

Publication number
JP2024534901A
JP2024534901A JP2024514038A JP2024514038A JP2024534901A JP 2024534901 A JP2024534901 A JP 2024534901A JP 2024514038 A JP2024514038 A JP 2024514038A JP 2024514038 A JP2024514038 A JP 2024514038A JP 2024534901 A JP2024534901 A JP 2024534901A
Authority
JP
Japan
Prior art keywords
syn
lys
seq
subject
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024514038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534901A5 (https=
Inventor
ジーン－コスメ ドダート，
Original Assignee
ヴァクシニティ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァクシニティ， インコーポレイテッド filed Critical ヴァクシニティ， インコーポレイテッド
Publication of JP2024534901A publication Critical patent/JP2024534901A/ja
Publication of JP2024534901A5 publication Critical patent/JP2024534901A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024514038A 2021-09-01 2022-09-01 シヌクレイノパチーの予防及び治療のための方法 Pending JP2024534901A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163239505P 2021-09-01 2021-09-01
US63/239,505 2021-09-01
PCT/US2022/075836 WO2023034914A2 (en) 2021-09-01 2022-09-01 Methods for the prevention and treatment of synucleinopathies

Publications (2)

Publication Number Publication Date
JP2024534901A true JP2024534901A (ja) 2024-09-26
JP2024534901A5 JP2024534901A5 (https=) 2025-09-29

Family

ID=85413127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024514038A Pending JP2024534901A (ja) 2021-09-01 2022-09-01 シヌクレイノパチーの予防及び治療のための方法

Country Status (10)

Country Link
US (1) US20240358806A1 (https=)
EP (1) EP4395894A4 (https=)
JP (1) JP2024534901A (https=)
KR (1) KR20240055785A (https=)
CN (1) CN118119403A (https=)
AU (1) AU2022337284A1 (https=)
CA (1) CA3230300A1 (https=)
MX (1) MX2024002684A (https=)
TW (1) TW202323275A (https=)
WO (1) WO2023034914A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137102A1 (en) * 2023-12-18 2025-06-26 Vaxxinity, Inc. Peptide immunogen compositions and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
EP1572894B1 (en) * 2001-11-21 2016-04-13 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
US8697082B2 (en) * 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
GB201512203D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
EP3638298A4 (en) * 2017-06-16 2021-05-05 United Neuroscience PEPTIDE IMMUNOGENS FROM THE C-TERMINAL END OF ALPHA-SYNUCLEIN-PROTEIN AND FORMULATIONS THEREOF FOR THE TREATMENT OF SYNUCLEINOPATHIA

Also Published As

Publication number Publication date
US20240358806A1 (en) 2024-10-31
TW202323275A (zh) 2023-06-16
WO2023034914A2 (en) 2023-03-09
CN118119403A (zh) 2024-05-31
MX2024002684A (es) 2024-05-16
EP4395894A2 (en) 2024-07-10
AU2022337284A1 (en) 2024-03-21
EP4395894A4 (en) 2025-08-06
CA3230300A1 (en) 2023-03-09
KR20240055785A (ko) 2024-04-29
WO2023034914A3 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
US9102752B2 (en) Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
JP5558834B2 (ja) シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
JP5249043B2 (ja) 治療ワクチン
ES2705586T3 (es) Prevención y tratamiento de enfermedades sinucleinopática y amiloidogénica
US20150232524A1 (en) Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
JP2010280663A (ja) Ｓｙｎｕｃｌｅｉｎ病の予防および治療
JP2024012498A (ja) タウペプチド免疫原構築物
JP2024534901A (ja) シヌクレイノパチーの予防及び治療のための方法
Yu et al. Effective DNA epitope chimeric vaccines for Alzheimer's disease using a toxin-derived carrier protein as a molecular adjuvant
JP2026505017A (ja) タウ及びアミロイドベータペプチド免疫原組成物及び関連方法
JP2023519104A (ja) 凝集膵島アミロイドポリペプチド（ｉａｐｐ）と関連する障害を予防及び治療するための、ｉａｐｐを標的とするペプチド免疫原
US20220023401A1 (en) Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type
JP2025523036A (ja) タウペプチド免疫原コンストラクト
DK2465533T3 (en) Methods and compositions comprising supramolecular constructs
JP2022131943A (ja) ワクチン、医薬及び糖尿病合併症治療薬
HK1127486B (zh) 治疗性疫苗

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250917